论文信息 - The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York - 字舞流文

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

R. Condos | M. Draine | A. Constantinescu | Aileen Espinal | K. Henthorne | E. DiMango | J. DeCelie‐Germana | Lynn Bonitz | D. Tsang | R. Giusti | Z. Messer | S. Romano | Janice Wang | Hossein Sadeghi | P. Walker | M. Berdella | A. Plachta | J. Simonson | C. Esposito | Theresa Frantzen | Ramona Ramdeo | Jessica Trentacoste | G. La Vecchia | R. Abdullah | Tara Gimeli | Jessenia Guzman | Soumia Hammouda | C. Keating | C. Kier | Alison T. Lennox | Carmen Liriano | E. Schwind | Teresa Stables-Carney | J. Guzmán | J. Trentacoste | T. Stables-Carney | A. Lennox | J. DeCelie-Germana | T. Frantzen

[1] A. Galvani,et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.

[2] A. Garcia-Basteiro,et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses , 2021, Nature Communications.

[3] J. Rakeman,et al. Prevalence of SARS-CoV-2 antibodies in New York City adults, June–October, 2020: a population-based survey , 2021, The Journal of infectious diseases.

[4] M. Mei-Zahav,et al. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020 , 2021, Journal of Cystic Fibrosis.

[5] D. Taruscio,et al. First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry , 2021, Journal of Cystic Fibrosis.

[6] M. Bonati,et al. Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown , 2020, Journal of Cystic Fibrosis.

[7] L. Risch,et al. Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies , 2020, medRxiv.

[8] C. Goss,et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis , 2020, Journal of Cystic Fibrosis.

[9] P. Boelle,et al. First Wave of COVID-19 in French Patients with Cystic Fibrosis , 2020, Journal of clinical medicine.

[10] D. Gruson,et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis , 2020, Journal of Cystic Fibrosis.

[11] B. Farber,et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. , 2020, JAMA.

[12] L. Dupont,et al. The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients , 2020, Journal of Cystic Fibrosis.

[13] A. Ashare,et al. SARS-CoV-2 (COVID-19) and cystic fibrosis , 2020, American journal of physiology. Lung cellular and molecular physiology.

[14] Nicholas Tsouklidis,et al. H1N1 Influenza Virus in Patients With Cystic Fibrosis: A Literature Review Examining Both Disease Entities and Their Association in Light of the 2009 Pandemic , 2020, Cureus.

[15] G. Parisi,et al. Cystic Fibrosis: Fighting Together Against Coronavirus Infection , 2020, Frontiers in Medicine.

[16] C. Olveira,et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey , 2020, Respiratory Medicine.

[17] V. Streva,et al. SARS-CoV-2 IgG antibody responses in New York City , 2020, Diagnostic Microbiology and Infectious Disease.

[18] M. Wener,et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.

[19] C. Goss,et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis , 2020, Journal of Cystic Fibrosis.

[20] J. Taylor-Cousar,et al. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease , 2020, European Respiratory Review.

[21] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[22] H. Renk,et al. Influenza A(H1N1)pdm09 and Cystic Fibrosis Lung Disease: A Systematic Meta-Analysis , 2014, PloS one.

[23] M. Teixeira,et al. ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis , 2013, British journal of pharmacology.

[24] G. Navis,et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[25] M. Corey,et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas , 2003, Gut.

[26] J. Luban. SARS-CoV-2 , 2020 .

[27] S. Baker,et al. A Population-Based Survey , 2017 .